Clinical pharmacology study of ipragliflozin in Japanese patients with type 1 diabetes mellitus: A phase 2, randomized, placebo‐controlled trial

類似資料

• Efficacy and safety of ipragliflozin add‐on therapy to insulin in Japanese patients with type 1 diabetes mellitus: A randomized, double‐blind, phase 3 trial
  著者:: Kaku, Kohei, 等
  出版事項: (2019)
• Long‐term (52‐week) efficacy and safety of ipragliflozin add‐on therapy to insulin in Japanese patients with type 1 diabetes mellitus: An uncontrolled, open‐label extension of a phase III study
  著者:: Kaku, Kohei, 等
  出版事項: (2020)
• Efficacy and safety of ipragliflozin as add-on therapy to insulin in Japanese patients with type 2 diabetes mellitus (IOLITE): a 36-week, open-label extension of a 16-week, randomized, placebo-controlled, double-blind study
  著者:: Ishihara, Hisamitsu, 等
  出版事項: (2018)
• A randomized, placebo‐controlled trial to assess the efficacy and safety of sitagliptin in Japanese patients with type 2 diabetes and inadequate glycaemic control on ipragliflozin
  著者:: Seino, Yutaka, 等
  出版事項: (2021)
• Insulin degludec in Japanese patients with type 1 diabetes mellitus: A randomized controlled trial
  著者:: Iwamoto, Yasuhiko, 等
  出版事項: (2013)